Abstract:The expression of EGLN2 gene was inhibited by the enrichment of YPA1 protein in EGLN2 promoter region after the transferring of YPA1 protein from cytoplasm to nucleus. EGLN2 protein promoted the degradation of HIF1‐α by polyubiquitination of HIF1‐α protein in cytoplasm. HIF1‐α, a regulator of anabolic glycolysis, promoted the transcription of a series of glycolytic gene expression, including GLUT1, Hk2 and LDHA, through binding to the hypoxia response element (HRE) of the target gene. Background Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive diseases and has remarkably high mortality rates. In recent years, altered metabolism has been shown to contribute to the maintenance of pancreatic cancer malignancies. However, the molecular mechanism underlying glucose metabolism reprogramming remains elusive. The aim of this study was to elucidate the role of Yes‐associated protein (YAP1), an important effector of the Hippo pathway, in the regulation of aerobic glycolysis in pancreatic cancer. Moreover, the contributions of YAP1 and its associated glycolytic enzymes to prognosis were assessed via The Cancer Genome Atlas (TCGA) dataset. Methods YAP1 expression was silenced by short hairpin RNA (shRNA), and its effects on glycolytic activity and mitochondrial respiration were analysed via Agilent Seahorse XF Analysers. The effects of YAP1 on hypoxia‐inducible factor‐1α (HIF‐1α) and its transcriptional activity on glycolytic genes were examined via shRNA‐mediated silencing of YAP1. The underlying mechanism by which YAP1 controls the HIF‐1α protein level was analysed by exploring the interaction between YAP1 and egg‐laying‐defective nine family (EGLN) members, which are well‐established regulators of the HIF‐1α protein level. Finally, the effects of YAP1, EGLN and glycolytic genes on prognosis were analysed via TCGA dataset. Results We found that silencing YAP1 expression inhibited anabolic glycolysis in pancreatic cancer cells. YAP1 was demonstrated to regulate the HIF‐1α protein level, transcriptional activity and the expression of HIF‐1α‐targeted glycolytic genes. In‐depth analysis demonstrated that EGLN2, a modulator of the HIF‐1α protein level, was a direct target of YAP1. Low EGLN2 expression was associated with a poor prognosis. By analysing TCGA dataset and performing immunohistochemical staining, we demonstrated that YAP1 expression was negatively correlated with EGLN2 expression at the mRNA level and protein levels. Conclusions The present study demonstrated that YAP1 positively regulates aerobic glycolysis by inhibiting EGLN2 expression, which results in an increased HIF‐1α protein level and transcriptional activity. YAP1 was positively regulated and significantly correlated with HIF‐1α‐targeted glycolytic genes, including glucose transporter type 1(GLUT1), hexokinase2 (HK2) and lactate dehydrogenase A (LDHA). Elevated YAP1 expression and concomitant downregulation of EGLN2 contributed to poor survival in patients with pancreatic cancer. Our results suggest that YAP1 may be a promising predictive marker and treatment target for human pancreatic cancer.

Yes-associated Protein 1 Exhibits Oncogenic Property in Gastric Cancer and Its Nuclear Accumulation Associates with Poor Prognosis.

YAP1 enhances cell proliferation, migration, and invasion of gastric cancer in vitro and in vivo

Yes-Associated Protein 1 As a Novel Prognostic Biomarker for Gastrointestinal Cancer: A Meta-Analysis

Yes-associated Protein 1 (YAP1) Promotes Human Gallbladder Tumor Growth Via Activation of the AXL/MAPK Pathway.

Overexpression of Yes-Associated Protein Contributes to Progression and Poor Prognosis of Non-Small-cell Lung Cancer.

YAP1 expression in colorectal cancer confers the aggressive phenotypes via its target genes

Prognostic Value Of Yes-Associated Protein 1 (Yap1) In Various Cancers: A Meta-Analysis

Expression of Yes-associated protein in gastric adenocarcinoma and its clinical significance

Yes-Associated Protein 1 (Yap) In The Growth And Tumorigenesis Of Ovarian Granulosa Cells.

Yes-Associated Protein 1 Promotes Adenocarcinoma Growth and Metastasis Through Activation of the Receptor Tyrosine Kinase Axl

Relationship between Yes-Associated Protein 1 and Prognosis of Digestive System Neoplasm: Quantitative Analysis and Bioinformatics Analysis Based on 4023 Patients

Expression of YES-associated protein (YAP) and its clinical significance in breast cancer tissues

YAP is a Critical Oncogene in Human Cholangiocarcinoma

YAP1 Overexpression Enhances the Aerobic Glycolysis Process via Suppression of EGLN2 in Pancreatic Ductal Adenocarcinoma

Yes-associated Protein (YAP) Predicts Poor Prognosis and Regulates Progression of Esophageal Squamous Cell Cancer Through Epithelial-Mesenchymal Transition.

YAP1 Mediates Gastric Adenocarcinoma Peritoneal Metastases That Are Attenuated by YAP1 Inhibition.

Clinical and Prognostic Significance of Yes-associated Protein in Colorectal Cancer

YAP is overexpressed in clear cell renal cell carcinoma and its knockdown reduces cell proliferation and induces cell cycle arrest and apoptosis.

Yes-associated Protein Expression is Associated with Poor Prognosis in Patients with Colorectal Cancer

The Prognostic Value of YAP1 on Clinical Outcomes in Human Cancers

Gene Regulation Network of Prognostic Biomarker YAP1 in Human Cancers: An Integrated Bioinformatics Study